Back to Neutral on Bayer - Analyst Blog

By Zacks | December 26, 2012 AAA

We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous Outperform recommendation on the stock are reflected in the current price. Bayer performed impressively in the third quarter of 2012, driven by an increase in revenues. Bayer's earnings per share during the third quarter of 2012 came in at ¬1.68 compared with ¬1.12 in the year-ago period. The company recorded 11.5% growth in revenues to ¬9,665 million. Growth was witnessed across all the major divisions at Bayer.

Bayer continues to expect 2012 earnings to increase by 10% year over year. Blood-thinner Xarelto, which has significant commercial potential, performed well during the quarter. The HealthCare unit of Bayer has co-developed Xarelto with Johnson & Johnson (JNJ).

We are also impressed by the US approval of Stivarga for use in treatment-experienced metastatic colorectal cancer patients. Bayer is also looking to get Stivarga approved for treating patients suffering from metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The US Food and Drug Administration (FDA) is reviewing the marketing application seeking approval of Stivarga for the GIST indication on a priority basis. Bayer is also seeking Japanese approval of Stivarga for the GIST indication. The sales potential of Stivarga would be further boosted if the regulatory authorities clear the drug for the GIST indication.

We are also positive on the European approval of eye-drug Eylea for treating patients suffering from neovascular (wet) age-related macular degeneration (wet AMD). Bayer is also seeking to expand the label of Eylea into other eye disorders. The HealthCare unit of Bayer has co-developed Eylea with Regeneron Pharmaceuticals (REGN).

However, we are mindful of the regulatory/pipeline setbacks at Bayer. In August 2012, Bayer and partner Sanofi (SNY) suffered a setback when the FDA issued a refuse-to-file letter regarding the marketing application submitted in June 2012, seeking approval to market Lemtrada for the treatment of relapsing multiple sclerosis.

Apart from this regulatory setback, Bayer suffered a pipeline setback in May 2012 when Nexavar (sorafenib), co-developed with Onyx Pharmaceuticals Inc. (ONXX), failed to prolong the overall survival in patients suffering from advanced non-squamous non-small cell lung cancer in a phase III study.

Moreover, the generic threat looming over many of Bayer's key products including the Yaz franchise (oral contraceptives) is another challenge for the company.

Related Analysis
  1. Stock Analysis

    New Data Runs Counter - Ahead of Wall Street

  2. Stock Analysis

    Bear of the Day: Cimarex Energy (XEC) - Bear of the Day

  3. Stock Analysis

    Closing the Books on Q3 Earnings Season - Earnings Trends

  4. Stock Analysis

    Bull of the Day: Skyworks Solutions (SWKS) - Bull of the Day

  5. These stocks have been weak, and despite rallies, investors might be better served by selling or shorting as opposed to buying.
    Chart Advisor

    Time To Take Profits On These 4 Rallying Stocks?

Trading Center